

ků a zejména pak irAEs měla věnovat větší pozornost již v rámci plánování prospektivních klinických studií. I vzhledem k výše zmíněnému předpokladu, že trend kombinování léčiv

k dosažení vyšší efektivity protinádorové léčby bude pokračovat, což může vést ke zvýšenému výskytu i vyšší závažnosti nežádoucích účinků terapie, je totiž jednoznačně zapotřebí

identifikovat nové genetické a mikrobiální biomarkery nejen imunitně podmíněných nežádoucích účinků a aktivně rozvíjet možnosti jejich předcházení (25).

LITERATURA

- Motzer RJ, Hutson TE, Tomczak P, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. *Journal of Clinical Oncology*. 2009;27(22):3584-3590.
- Alonso-Gordo A, García-Bermejo ML, Grande E, et al. Targeting Tyrosine Kinases in Renal Cell Carcinoma: „New Bullets against Old Guys“. *International Journal of Molecular Sciences*. 2019;20(8):1901.
- Heng DY, Xie W, Regan MM, et al. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor – Targeted Agents: Results From a Large, Multicenter Study. *Journal of Clinical Oncology*. 2009;27(34):5794-5799.
- Haanen JBAG, Larkin J, Choueiri TK, et al. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. *ESMO Open*. 2023;8(3):101210.
- SÚKL, Detail varianty léčivého přípravku (YERVOY – 5MG/ML INF CNC SOL 1X10ML) [Internet] [Available from: https://prehledy.sukl.cz/prehled_liciv.html#/liciva/0185101].
- Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. *The Lancet Oncology*. 2023;24(3):228-238.
- Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. *Lancet*. 2023;402(10397):185-195.
- Hallare J, Gerriets V. Half Life. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
- EMA, Sutent, Inlyta, Votrient, Cabometyx, Kisplyx : EPAR – Product information [Internet] [Available from: <https://www.ema.europa.eu/en/medicines/human>].
- EMA, Afinitor : EPAR – Product information [Internet] Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor#product-information-section>.
- Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. *Cancer*. 2010;116(18):4256-4265.
- NCCN Guidelines, Kidney Cancer, Version: 1.2024, [Internet].
- Dutcher JP, Flippot R, Fallah J, Escudier B. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment – Cytokines, Targeted Therapy, and Immunotherapy. *American Society of Clinical Oncology Educational Book*. 2020(40):418-435.
- Kyllarová A, Kubeček O, Trojanová P, et al. Immunotherapy related toxicities. *Onkologie*. 2017;11:83-87.
- Lakomý R, Poprach A. Sideeffects of Modern Immunotherapy and How to Solve Them in the Clinics. *Klin Onkol*. 2015;28 Suppl 4:4s103-114.
- Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomised, open-label, phase 3 CheckMate 025 trial. *Cancer*. 2020;126(18):4156-4167.
- Powles T, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2022;23(9):1133-1144.
- Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open*. 2020;5(6):e001079.
- Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. *The Lancet Oncology*. 2020;21(12):1563-1573.
- Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. *The Lancet Oncology*. 2022;23(7):888-898.
- Grünwald V, Voss MH, Rini BI, et al. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. *British journal of cancer*. 2020;123(6):898-904.
- Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. *New England Journal of Medicine*. 2023;388(19):1767-1778.
- Choueiri TK, Plimack ER, Powles T, et al. Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC). *Journal of Clinical Oncology*. 2022;40(6 suppl):TPS399-TPS.
- Choueiri TK, McDermott DF, Merchan J, et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. *The Lancet Oncology*. 2023;24(5):553-562.
- Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. *Nature Communications*. 2022;13(1).

35.

VÝROČNÍ SETKÁNÍ DĚTSKÝCH UROLOGŮ



5.–6. 4. 2024 / OLOMOUC / Central Park Flora

Bližší informace na: <https://uro.registrace-solen.cz>

